Delivery Order SPE2DR25D3201-SPE2DR26FT7GH

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 26, 2026, for Ocrevus 300 mg/10 mL vials with a ceiling value of $76,913.10.</p> <p>Place of performance is Conshohocken, PA. The order has an ultimate completion date of March 19, 2026, and is priced on a firm fixed-price basis.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 11, 2026, for $25,637.70 ceiling value to supply Ocrevus 300 mg/10 ml vial medication.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is March 5, 2026. The order was issued under firm fixed-price pricing with no set-aside.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 20, 2026, for Ocrevus 300 mg/10 mL vials, with a ceiling value of $25,637.70.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is March 13, 2026. The order carries firm fixed pricing and was not issued under a set-aside.</p>

<p>The Defense Logistics Agency issued a $51,493.52 delivery order to Amerisourcebergen Drug Corp on February 24, 2026, for OCREVUS 300 mg/10 mL vials.</p> <p>The order is placed against Amerisourcebergen's Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. Place of performance is Conshohocken, PA. The ultimate completion date is March 17, 2026. Pricing is firm fixed price with no set-aside applied.</p>

The Defense Logistics Agency issued a $128,188.50 firm fixed-price delivery order to Amerisourcebergen Drug Corp on March 3, 2026, for Ocrevus 300 mg/10 mL vials. The order is placed against the DLA Troop Support Medical IDC, a $999,999,999 indefinite delivery contract running through December 2026 that supplies pharmaceutical products and medical supplies to support military healthcare programs globally. Place of performance is Conshohocken, PA. Ultimate completion date is March 24, 2026.

<p>The Defense Logistics Agency issued a $76,913.10 delivery order to Amerisourcebergen Drug Corp on March 5, 2026, for Ocrevus 300 mg/10 ml vials under a firm fixed-price arrangement with an ultimate completion date of March 26, 2026.</p> <p>Place of performance is Conshohocken, PA. The order was issued without a set-aside.</p>

<p>The Defense Logistics Agency issued a delivery order to AmerisourceBergen Drug Corp on February 26, 2026, with a ceiling value of $76,913.10 for OCREVUS 300 mg/10 mL vials.</p> <p>The order is issued under the DLA Troop Support Medical IDC held by parent company Cencora, Inc., valued at up to $999,999,999.00 through December 2026. Place of performance is Conshohocken, PA. The order carries an ultimate completion date of March 19, 2026 and is priced on a firm fixed-price basis.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 10, 2026, for $76,913.10 under a parent Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX) for Ocrevus 300 mg/10 mL vials.</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of March 4, 2026. No set-aside was used.</p>

The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 10, 2026, for Ocrevus 300 mg/10 ml vial 10 ml, with a ceiling value of $76,913.10. Place of performance is Conshohocken, PA. The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (SPE2DX), a global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026, which enables supply of a comprehensive range of pharmaceutical products and medical supplies...

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $75,998.88 and firm fixed pricing. This non-set-aside, competitively awarded delivery order is scheduled for completion by December 3, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Ocrevus is a prescription pharmaceutical used primarily in the treatment of multiple sclerosis,...